We know that there is only a percentage of clinical trials that can be truly “virtual” and that there are some studies that must remain 100% site- and/or paper-based. Driven by the increased focus on lowering the amount of patient burden associated with trials, the industry is interested in turning the “Trial Dial” to introduce some level of virtualization on more trials. This might include, for example, remote electronic consent, followed by a site visit, followed by the remote use of eCOA tools by the patient before returning to the site for lab tests or treatment. In some studies there is a dramatic reduction in site visits with assessments being provided remotely. Medidata believes the future of most clinical research will consist of some level of virtualization.